Zanubrutinib for treating Waldenstrom’s macroglobulinaemia
Technology appraisal guidance
Reference number: TA833
Published:
The timelines for this appraisal have been revised and the first appraisal committee meeting is now scheduled to take place on 7 September 2021. This is to allow the company to address the decision problem in the final scope in its submission.